Luye Licenses China Rights To Cancer Drug From Hanmi Pharma
This article was originally published in PharmAsia News
Executive Summary
Luye Pharma Group has licensed Hanmi Pharmaceutical's poziotinib, a pan-HER inhibitor to treat cancer, for exclusive rights in China.